Pathogenesis of pain in peripheral diabetic neuropathy

Current Diabetes Reports

Volumn 7, Issue 6, 2007, Pages 429-434

  Calcutt, Nigel A ^b   Backonja, Miroslav Misha ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 1,5 ISOQUINOLINEDIOL; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ADENOSINE TRIPHOSPHATE; ALDOSE REDUCTASE INHIBITOR; ALLOPURINOL; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIOXIDANT; ASIMADOLINE; BENFOTIAMINE; BIOLOGICAL MARKER; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CIZOLIRTINE; CYCLOOXYGENASE 2; DULOXETINE; GLUTAMATE CARBOXYPEPTIDASE II; HARKOSERIDE; ICI 222155; JANUS KINASE INHIBITOR; KAPPA OPIATE RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PREGABALIN; PROGLUMIDE; RESVERATROL; TAURINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLODYNIA; ASSAY; CLINICAL RESEARCH; CLINICAL TRIAL; DIABETIC NEUROPATHY; DISEASE MODEL; DRUG MECHANISM; HUMAN; HYPERALGESIA; NEUROPATHIC PAIN; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; STREPTOZOCIN DIABETES; VALIDATION PROCESS;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; HUMANS; HYPERALGESIA; PAIN;

EID: 37349090098     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0072-9     Document Type: Review

References (70)

1. Jensen TS, Backonja MM, Hernandez Jimenez S, et al.: New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res 2006, 3:108-119.
2. Ji RR, Strichartz G: Cell signaling and the genesis of neuropathic pain. Sci STKE 2004, 2004(252):reE14.
3. Backonja MM, Galer B: Pain assessment and evaluation of patients with neuropathic pain. Neurol Clin 1998, 16:775-790.
4. Woolf CJ, Mannion RJ: Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999, 353:1959-1964.
5. Kelly Getz K, Cook T, Backonja MM: Pain ratings at the thresholds are necessary for interpretation of quantitative sensory testing. Muscle Nerve 2005, 32:179-184.
6. Rolke R, Baron R, Maier C, et al.: Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain 2006, 123:231-243.
7. Yarnitsky D, Sprecher E: Thermal testing: normative data and repeatability for various test algorithms. J Neurol Sci 1994, 125:39-45.
8. Dyck PJ, O'Brien PC: Approaches to quantitative cutaneous sensory assessment. In Quantification of Neurologic Deficits. Edited by Munsat TL. Boston: Butterworths; 1997:187-195.
9. Harju EL: Cold and warmth perception mapped for age, gender, and body area. Somatosens Mot Res 2002, 19:61-75.
10. Bennett MI, Attal N, Backonja MM, et al.: Using screening tools to identify neuropathic pain. Pain 2007, 127:199-203.
11. Bennett MI: The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 2001, 92:147-157.
12. Backonja M, Krause S: Neuropathic pain questionnaire-short form. Clin J Pain 2003, 19:315-316.
13. Bouhassira D, Attal N. Alchaar H, et al.: Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005, 14:29-36.
14. Freynhagen R, Baron R, Gockel U, Tolle TR: painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006, 22:1911-1120.
15. Krause S, Backonja M: Development of a neuropathic pain questionnaire. Clin J Pain 2003, 19:306-314.
16. Bouhassira D. Attal N, Fermanian J, et al.: Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004, 108:248-257.
17. Lauria G, Lombardi R: Skin biopsy: a new tool for diagnosing peripheral neuropathy. BMJ 2007, 334:1159-1162.
18. Walk D, Wendelschafer-Crabb G, Davey C, Kennedy W: Concordance between epidermal nerve fiber density and sensory examination in patients with symptoms of idiopathic small fiber neuropathy. J Neurol Sci 2007, 255:23-26.
19. Gibbons CH, Griffin JW, Polydefkis M, et al.: The utility of skin biopsy for prediction of progression in suspected small fiber neuropathy. Neurology 2006, 66:256-258.
20. Uceyler N, Rogausch JP, Toyka KV, Sommer C: Differential expression of cytokines in painful and painless neuropathies. Neurology 2007, 69:42-49.
21. Quattrini C, Harris ND, Malik RA, Tesfaye S: Impaired skin microvascular reactivity in painful diabetic neuropathy. Diabetes Care 2007, 30:655-659.
22. Malik RA, Kallinikos P, Abbott CA, et al.: Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia 2003, 46:683-688.
23. Quattrini C, Tavakoli M, Jeziorska M, et al.: Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes 2007, 56:2148-2154.
24. Wernicke JF, Pritchett YL, D'Souza DN, et al.: A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006, 67:1411-1420.
25. Raskin J, Pritchett YL, Wang F, et al.: A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005, 6:346-356.
26. Richter RW, Portenoy R, Sharma U, et al.: Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005, 6:253-260.
27. Lesser H, Sharma U, LaMoreaux L, Poole RM: Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004, 63:2104-2110.
28. Backonja MM, Irving GA, Argoff CE: Rational multidrug therapy in the treatment of neuropathic pain. Curr Pain Headache Rep 2006, 10:34-38.
29. Gilron I, Bailey JM, Tu D, et al.: Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005, 352:1324-1334.
30. Christianson JA, Ryals JM, Johnson MS, et al.: Neurotrophic modulation of myelinated cutaneous innervation and mechanical sensory loss in diabetic mice. Neuroscience 2007, 145:303-313.
31. Johnson MS, Ryals JM, Wright DE: Diabetes-induced chemogenic hypoalgesia is paralleled by attenuated stimulus-induced fos expression in the spinal cord of diabetic mice. J Pain 2007, 8:637-649.
32. Kamiya H, Murakawa Y, Zhang W, Sima AA: Unmyelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes. Diabetes Metab Res Rev 2005, 21:448-458.
33. Kamiya H, Zhang W, Ekberg K, et al.: C-Peptide reverses nociceptive neuropathy in type 1 diabetes. Diabetes 2006, 55:3581-3587.
34. Zhang W, Murakawa Y, Wozniak KM, et al.: The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J Neurol Sci 2006, 247:217-223.
35. Drel VR, Mashtalir N, Ilnytska O, et al.: The leptin-deficient (ob/ ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity. Diabetes 2006, 55:3335-3343.
36. Li F, Abatan OI, Kim H, et al.: Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats. Neurobiol Dis 2006, 22:669-676.
37. Vareniuk I, Pavlov IA, Dret VR, et al.: Nitrosative stress and peripheral diabetic neuropathy in leptin-deficient (ob/ob) mice. Exp Neurol 2007, 205:425-436.
38. Jourdan D, Ardid D, Eschalier A: Analysis of ultrasonic vocalisation does not allow chronic pain to be evaluated in rats. Pain 2002, 95:165-173.
39. Han JS, Bird GC, Li W, et al.: Computerized analysis of audible and ultrasonic vocalizations of rats as a standardized measure of pain-related behavior. J Neurosci Methods 2005, 141:261-269.
40. Morgado C, Tavares I: C-fos expression at the spinal dorsal horn of streptozotocin-induced diabetic rats. Diabetes Metab Res Rev 2007, May 16; [Epub ahead of print].
41. Otto M, Bak S, Bach FW, et al.: Pain phenomena and possible mechanisms in patients with painful polyneuropathy. Pain 2003, 101:187-192.
42. Calcutt NA: Potential mechanisms of neuropathic pain in diabetes. Int Rev Neurobiol 2002, 50:205-228.
43. Beyreuther B, Callizot N, Stohr T: Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol 2006, 539:64-70.
44. Jolivalt CG, Ramos KM, Herbetsson K, et al.: Therapeutic efficacy of prosaposin-derived peptide on different models of allodynia. Pain 2006, 121:14-21.
45. Jolivalt CG, Jiang Y, Freshwater JD, et al.: Dynorphin A, kappa opioid receptors and the antinociceptive efficacy of asimadoline in streptozotocin-induced diabetic rats. Diabetologia 2006, 49:2775-2285.
46. Joseph EK, Levine JD: Mitochondrial electron transport in models of neuropathic and inflammatory pain. Pain 2006, 121:105-114.
47. Sanchez-Ramirez GM, Caram-Salas NL, Rocha-Gonzalez HI, et al.: Benfotiamine relieves inflammatory and neuropathic pain in rats. Eur J Pharmacol 2006, 530:48-53.
48. Aubel B, Kayser V, Farre A, et al.: Evidence for adenosine- and serotonin-mediated antihyperalgesic effects of cizolirtine in rats suffering from diabetic neuropathy. Neuropharmacology 2007, 52:487-496.
49. Khroyan TV, Polgar WE, Orduna J, et al.: Anti-nociceptive and anti-allodynic effects of a high affinity NOP hexapeptide [Ac-RY(3-Cl)YRWR-NH2] (Syn 1020) in rodentsn. Eur J Pharmacol 2007, 560:29-35.
50. Matsunaga A, Kawamoto M, Shiraishi S, et al.: Intrathecally administered COX-2 but not COX-1 or COX-3 inhibitors attenuate streptozotocin-induced mechanical hyperalgesia in rats. Eur J Pharmacol 2007, 554:12-17.
51. Ramos KM, Jiang Y, Svensson CI, Calcutt NA: Pathogenesis of spinally mediated hyperalgesia in diabetes. Diabetes 2007, 56:1569-1576.
52. Torres-Lopez JE, Juarez-Rojop IE, Granados-Soto V, et al.: Peripheral participation of cholecystokinin in the morphine-induced peripheral antinociceptive effect in non-diabetic and diabetic rats. Neuropharmacology 2007, 52:788-795.
53. Daulhac L, Mallet C, Courteix C, et al.: Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependent mechanisms. Mol Pharmacol 2006, 70:1246-1254.
54. Ilnytska O, Lyzogubov VV, Stevens MJ, et al.: Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes 2006, 55:1686-1694.
55. Inkster ME, Cotter MA, Cameron NE: Treatment with the xanthine oxidase inhibitor, allopurinol, improves nerve and vascular function in diabetic rats. Eur J Pharmacol 2007, 561:63-71.
56. Kumar A, Kaundal RK, Iyer S, Sharma SS: Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci 2007, 80:1236-1244.
57. Stevens MJ, Li F, Drel VR, et al.: Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats. J Pharmacol Exp Ther 2007, 320:458-464.
58. Calcutt NA, Freshwater JD, Mizisin AP: Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia 2004, 47:718-724.
59. Romanovsky D, Cruz NF, Dienel GA, Dobretsov M: Mechanical hyperalgesia correlates with insulin deficiency in normoglycemic streptozotocin-treated rats. Neurobiol Dis 2006, 24:384-394.
60. Hoybergs YM, Meert TF: The effect of low-dose insulin on mechanical sensitivity and allodynia in type I diabetes neuropathy. Neurosci Lett 2007, 417:149-154.
61. Toth C, Brussee V, Zochodne DW: Remote neurotrophic support of epidermal nerve fibres in experimental diabetes. Diabetologia 2006, 49:1081-1088.
62. Huang TJ, Price SA, Chilton L, et al.: Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. Diabetes 2003, 52:2129-2136.
63. Wang XL, Zhang HM, Chen SR, Pan HL: Altered synaptic input and GABAB receptor function in spinal superficial dorsal horn neurons in rats with diabetic neuropathy. J Physiol 2007, 579:849-861.
64. Malmberg AB, O'Connor WT, Glennon JC, et al.: Impaired formalin-evoked changes of spinal amino acid levels in diabetic rats. Brain Res 2006, 1115:48-53.
65. Tanabe M, Shimizu S, Takabayashi K, et al.: Functional alteration of inhibitory influences on spinal motor output in painful diabetic neuropathy in rats. Neurosci Lett 2005, 389:152-156.
66. Calcutt NA, Li L, Yaksh TL, Malmberg AB: Different effects of two aldose reductase inhibitors on nociception and prostaglandin E. Eur J Pharmacol 1995, 285:189-197.
67. Freshwater JD, Svensson CI, Malmberg AB, Calcutt NA: Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats. Diabetes 2002, 51:2249-2255.
68. Jiang Y, Calcutt NA, Ramos KM, Mizisin AP: Novel sites of aldose reductase immunolocalization in normal and streptozotocin-diabetic rats. J Peripher Nerv Syst 2006, 11:274-285.
69. Waxman SG, Hains BC: Fire and phantoms after spinal cord injury: Na+ channels and central pain. Trends Neurosci 2006, 29:207-215.
70. Flor H, Nikolajsen L, Staehelin Jensen T: Phantom limb pain: a case of maladaptive CNS plasticity? Nat Rev Neurosci 2006, 7871-881.